ALLMedicine™ Gastrointestinal Stromal Tumors Center
Research & Reviews 3,657 results
https://doi.org/10.1186/s12893-021-01208-0 10.1146/annurev-med-043010-091813 10.1007/s004280000338 10.1007/978-1-4939-7471-9_12 10.1158/1055-9965.EPI-14-1002 10.1016/j.hoc.2008.11.005 10.1001/jamaoncol.2016.0256 10.1038/modpathol.2013.173 10.1309/AJCPPCKGA2QGBJ1R 10.1186/s12967-016-1075-6 10.1186/s13000-020-0926-x 10.1111/his.14133 10.1245/s10434-014-3729-z
BMC Surgery; Song Q, Li G et. al.
Apr 21st, 2021 - Gastrointestinal stromal tumors rarely occur in children, but when they do, their biological behavior and histopathological patterns differ from those of adults. A 13-year-old boy with a gastrointestinal stromal tumor was characterized by a rare g...
https://doi.org/10.1007/s00330-021-07961-3 10.21037/jgo.2018.08.20 10.1016/S0140-6736(13)60106-3 10.1016/j.ejca.2017.03.025 10.1016/j.humpath.2008.06.025 10.1016/S1470-2045(11)70299-6 10.1007/s11547-006-0063-y 10.1016/S1726-4901(08)70022-4 10.1016/j.crad.2010.02.006 10.2214/AJR.14.12870 10.1259/bjr.20150085 10.1371/journal.pone.0144277 10.1102/1470-7330.2012.0048 10.1007/s00330-016-4515-z 10.1007/s00261-016-1033-z 10.1007/s00330-019-06561-6 10.1097/RCT.0000000000000526 10.1002/cam4.1737 10.1007/s00261-018-1511-6 10.1007/s00330-015-4172-7 10.1007/s00330-018-5945-6 10.1007/s00261-017-1370-6 10.1007/s00330-005-0091-3 10.1038/s41598-019-43659-9 10.1200/JCO.2006.07.3049 10.1093/annonc/mdy095 10.1016/j.ejso.2016.03.032 10.21037/jgo.2016.09.15 10.5858/2006-130-1466-GSTROM 10.1007/s00261-018-1865-9 10.1007/s00261-018-1803-x
European Radiology; Cannella R, Tabone E et. al.
Apr 21st, 2021 - To investigate the correlation between CT imaging features and risk stratification of gastrointestinal stromal tumors (GISTs), prediction of mutation status, and prognosis. This retrospective dual-institution study included patients with pathologi...
https://doi.org/10.1007/s10555-021-09961-7 10.2217/fon-2016-0192 10.1016/S1470-2045(20)30269-2
Cancer Metastasis Reviews; Al-Share B, Alloghbi A et. al.
Apr 20th, 2021 - Gastrointestinal stromal tumors (GIST) are rare neoplasms arising from the interstitial cell of Cajal in the gastrointestinal tract. Two thirds of GIST in adult patients have c-Kit mutation and smaller fractions have platelet derived growth factor...
https://doi.org/10.1016/j.amjsurg.2021.03.062
American Journal of Surgery; Shannon AB, Song Y et. al.
Apr 19th, 2021 - Localized gastrointestinal stromal tumors (GISTs) are rare tumors typically managed with surgery, but outcomes among octogenarians remain less studied. Octogenarian patients with stage I-III gastric GISTs were identified from the National Cancer D...
https://doi.org/10.1097/PAS.0000000000001720
The American Journal of Surgical Pathology; Papke DJ, Forgó E et. al.
Apr 16th, 2021 - Platelet-derived growth factor receptor A (PDGFRA) is a receptor tyrosine kinase that is activated by mutations in 10% of gastrointestinal stromal tumors (GISTs) and 55% to 70% of inflammatory fibroid polyps. PDGFRA-mutant GISTs are usually epithe...
Guidelines 11 results
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist
May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/
May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295840
World Journal of Gastroenterology; Li J, Wang M et. al.
Dec 25th, 2018 - Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or conse...
https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy095/5004450
Casali, P. G.
May 27th, 2018 - Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year. This only covers clinically relevant GISTs, since, if investigated, a much higher number of lesions ≤ 1 cm in diameter (mic.
https://doi.org/10.1093/annonc/mdu360
Annals of Oncology : Official Journal of the European Soc... Bellera CA, Penel N et. al.
Jul 29th, 2014 - The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-even...
Drugs 2 results see all →
Clinicaltrials.gov 3,849 results
https://doi.org/10.1186/s12893-021-01208-0 10.1146/annurev-med-043010-091813 10.1007/s004280000338 10.1007/978-1-4939-7471-9_12 10.1158/1055-9965.EPI-14-1002 10.1016/j.hoc.2008.11.005 10.1001/jamaoncol.2016.0256 10.1038/modpathol.2013.173 10.1309/AJCPPCKGA2QGBJ1R 10.1186/s12967-016-1075-6 10.1186/s13000-020-0926-x 10.1111/his.14133 10.1245/s10434-014-3729-z
BMC Surgery; Song Q, Li G et. al.
Apr 21st, 2021 - Gastrointestinal stromal tumors rarely occur in children, but when they do, their biological behavior and histopathological patterns differ from those of adults. A 13-year-old boy with a gastrointestinal stromal tumor was characterized by a rare g...
https://doi.org/10.1007/s00330-021-07961-3 10.21037/jgo.2018.08.20 10.1016/S0140-6736(13)60106-3 10.1016/j.ejca.2017.03.025 10.1016/j.humpath.2008.06.025 10.1016/S1470-2045(11)70299-6 10.1007/s11547-006-0063-y 10.1016/S1726-4901(08)70022-4 10.1016/j.crad.2010.02.006 10.2214/AJR.14.12870 10.1259/bjr.20150085 10.1371/journal.pone.0144277 10.1102/1470-7330.2012.0048 10.1007/s00330-016-4515-z 10.1007/s00261-016-1033-z 10.1007/s00330-019-06561-6 10.1097/RCT.0000000000000526 10.1002/cam4.1737 10.1007/s00261-018-1511-6 10.1007/s00330-015-4172-7 10.1007/s00330-018-5945-6 10.1007/s00261-017-1370-6 10.1007/s00330-005-0091-3 10.1038/s41598-019-43659-9 10.1200/JCO.2006.07.3049 10.1093/annonc/mdy095 10.1016/j.ejso.2016.03.032 10.21037/jgo.2016.09.15 10.5858/2006-130-1466-GSTROM 10.1007/s00261-018-1865-9 10.1007/s00261-018-1803-x
European Radiology; Cannella R, Tabone E et. al.
Apr 21st, 2021 - To investigate the correlation between CT imaging features and risk stratification of gastrointestinal stromal tumors (GISTs), prediction of mutation status, and prognosis. This retrospective dual-institution study included patients with pathologi...
https://doi.org/10.1007/s10555-021-09961-7 10.2217/fon-2016-0192 10.1016/S1470-2045(20)30269-2
Cancer Metastasis Reviews; Al-Share B, Alloghbi A et. al.
Apr 20th, 2021 - Gastrointestinal stromal tumors (GIST) are rare neoplasms arising from the interstitial cell of Cajal in the gastrointestinal tract. Two thirds of GIST in adult patients have c-Kit mutation and smaller fractions have platelet derived growth factor...
https://doi.org/10.1016/j.amjsurg.2021.03.062
American Journal of Surgery; Shannon AB, Song Y et. al.
Apr 19th, 2021 - Localized gastrointestinal stromal tumors (GISTs) are rare tumors typically managed with surgery, but outcomes among octogenarians remain less studied. Octogenarian patients with stage I-III gastric GISTs were identified from the National Cancer D...
https://doi.org/10.1097/PAS.0000000000001720
The American Journal of Surgical Pathology; Papke DJ, Forgó E et. al.
Apr 16th, 2021 - Platelet-derived growth factor receptor A (PDGFRA) is a receptor tyrosine kinase that is activated by mutations in 10% of gastrointestinal stromal tumors (GISTs) and 55% to 70% of inflammatory fibroid polyps. PDGFRA-mutant GISTs are usually epithe...
News 161 results
https://www.staging.medscape.com/viewarticle/934648
Jul 26th, 2020 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a thumbs up to two new oncology drugs. The Committee has recommended granting conditional marketing authorization for avapritinib (Ayvakit, Bluepr...
https://www.medscape.com/viewarticle/934648
Jul 26th, 2020 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a thumbs up to two new oncology drugs. The Committee has recommended granting conditional marketing authorization for avapritinib (Ayvakit, Bluepr...
https://www.medscape.com/viewarticle/933412
Jul 5th, 2020 - NEW YORK (Reuters Health) - Treatment with oral ripretinib significantly prolonged survival in patients with advanced gastrointestinal stromal tumors (GIST) who did not respond or were intolerant to three other tyrosine-kinase inhibitors in the IN...
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist
May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/
May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/...
